# EcoR1 Capital's Biotech Investments: 16 Startups in Its Portfolio (2026) > The 16 Biotech startups EcoR1 Capital has backed, by stage: $3.7B raised between them. From the rounds we track; updated nightly. Source: https://millionrounds.com/portfolio-maps/ecor1-capital-biotech-portfolio (Millionrounds; every figure on the page links to its filing or article) ## Series C and later 7 - [ElevateBio](https://millionrounds.com/company/elevatebio) - [Arcus Biosciences](https://millionrounds.com/company/arcus-biosciences) - [*A* Atreca](https://millionrounds.com/company/atreca) - [Dewpoint Therapeutics](https://millionrounds.com/company/dewpoint-therapeutics) - [Metacrine](https://millionrounds.com/company/metacrine) - [*C* Codiak](https://millionrounds.com/company/codiak) - [*O* ORIC](https://millionrounds.com/company/oric) ## Series B 6 - [Intellia Therapeutics](https://millionrounds.com/company/intellia-therapeutics) - [Editas Medicine](https://millionrounds.com/company/editas-medicine) - [AlloVir](https://millionrounds.com/company/allovir) - [Atara Biotherapeutics](https://millionrounds.com/company/atara-biotherapeutics) - [*PT* Prevail Therapeutics](https://millionrounds.com/company/prevail-therapeutics) - [*A* Avidity](https://millionrounds.com/company/avidity) ## Series A 3 - [Nuvation Bio](https://millionrounds.com/company/nuvation-bio) - [*P* Prevail](https://millionrounds.com/company/prevail) - [*A* Accent](https://millionrounds.com/company/accent) ## Segment by segment ### Series C and later 7 startups · $1.8B raised - [**ElevateBio**](https://millionrounds.com/company/elevatebio) ElevateBio is a biotechnology company based in Waltham, Massachusetts, founded in 2017. United States $551M - [**Arcus Biosciences**](https://millionrounds.com/company/arcus-biosciences) Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer. United States $427M - [*A* **Atreca**](https://millionrounds.com/company/atreca) Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. United States $313M - [**Dewpoint Therapeutics**](https://millionrounds.com/company/dewpoint-therapeutics) Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates. United States $196M - [**Metacrine**](https://millionrounds.com/company/metacrine) Metacrine is a clinical-stage bio pharmaceutical company focused on building an innovative pipeline of best-in-class drugs. United States $173M - [*C* **Codiak**](https://millionrounds.com/company/codiak) United States $77M - [*O* **ORIC**](https://millionrounds.com/company/oric) United States $50M ### Series B 6 startups · $1.1B raised - [**Intellia Therapeutics**](https://millionrounds.com/company/intellia-therapeutics) Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments. United States $485M - [**Editas Medicine**](https://millionrounds.com/company/editas-medicine) Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases. United States $335M - [**AlloVir**](https://millionrounds.com/company/allovir) AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. United States $120M - [**Atara Biotherapeutics**](https://millionrounds.com/company/atara-biotherapeutics) Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company. United States $69M - [*PT* **Prevail Therapeutics**](https://millionrounds.com/company/prevail-therapeutics) United States $50M - [*A* **Avidity**](https://millionrounds.com/company/avidity) Avidity is a RNA therapeutics software solutions provider company. United States $32M ### Series A 3 startups · $790M raised - [**Nuvation Bio**](https://millionrounds.com/company/nuvation-bio) Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology. United States $675M - [*P* **Prevail**](https://millionrounds.com/company/prevail) - $75M - [*A* **Accent**](https://millionrounds.com/company/accent) United States $40M **How this map is made.** Every startup here works in Biotech and has raised money in a round we track that names EcoR1 Capital as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026. ## More portfolio maps [All portfolios](https://millionrounds.com/portfolio-maps) [Co-investors **Who invests with EcoR1 Capital** 31 co-investors](https://millionrounds.com/portfolio-maps/ecor1-capital-co-investors)[Sector portfolio **RA Capital Management's Biotech portfolio** 197 startups · $38B](https://millionrounds.com/portfolio-maps/ra-capital-management-biotech-portfolio)[Sector portfolio **OrbiMed's Biotech portfolio** 176 startups · $28B](https://millionrounds.com/portfolio-maps/orbimed-biotech-portfolio)[Sector portfolio **Pioneer Fund's AI portfolio** 171 startups · $2.8B](https://millionrounds.com/portfolio-maps/pioneer-fund-2-ai-portfolio)[Sector portfolio **Gaingels' AI portfolio** 146 startups · $14B](https://millionrounds.com/portfolio-maps/gaingels-ai-portfolio)[Sector portfolio **Cormorant Asset Management's Biotech portfolio** 95 startups · $21B](https://millionrounds.com/portfolio-maps/cormorant-asset-management-biotech-portfolio) ## Raising from investors like EcoR1 Capital? Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports. [Find investors](https://millionrounds.com/login?join=1&next=/app/investors)[Market maps](https://millionrounds.com/market-maps)